Alphyn Biologics

Alphyn Biologics is a clinical-stage company focused on dermatology. Based on its AB-101 platform, it develops first-class multi-target treatments for severe and prevalent skin conditions. Its lead candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in phase 2a clinical trials. AB-101a has demonstrated strong safety and is being developed to uniquely target both bacterial and immune system components of AD, making it an ideal treatment for both infected and non-infected AD. Alphyn's AB-101 platform contains multiple bioactive compounds, providing various mechanisms of action to support a robust pipeline of dermatological treatments with potential safety and efficacy, as well as advantages in regulatory marketing authorization.